Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) - Cantor Fitzgerald lifted their FY2025 EPS estimates for Zealand Pharma A/S in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the company will post earnings per share of $11.64 for the year, up from their prior forecast of $11.57. The consensus estimate for Zealand Pharma A/S's current full-year earnings is ($2.19) per share.
Separately, William Blair upgraded shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.
View Our Latest Stock Report on Zealand Pharma A/S
Zealand Pharma A/S Stock Performance
Shares of ZLDPF stock traded down $4.05 during mid-day trading on Wednesday, hitting $70.08. The stock had a trading volume of 1,525 shares, compared to its average volume of 923. Zealand Pharma A/S has a fifty-two week low of $57.97 and a fifty-two week high of $141.74. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The company's 50-day simple moving average is $66.46 and its 200-day simple moving average is $85.71. The firm has a market cap of $4.98 billion, a PE ratio of -29.69 and a beta of 0.74.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. The firm had revenue of $1.14 million for the quarter, compared to the consensus estimate of $248.61 million. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%.
Zealand Pharma A/S Company Profile
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Recommended Stories
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
